Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Varun Mittal, MD, Mimi Lo, PharmD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Thomas G. Martin, III, MD, Rebecca L. Olin, MD, Catherine C. Smith, MD, Aaron C. Logan, MD PhD

Blood (2019) 134 (Supplement_1): 5089.

https://doi.org/10.1182/blood-2019-129514

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

https://doi.org/10.1182/blood-2019-129638

Published: 2019

Journal Articles

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Kelly L. Schoenbeck, MD, Giselle Salmasi, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Aaron C. Logan, MD PhD, Rebecca L. Olin, MD, Andrew D. Leavitt, MD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1165.

https://doi.org/10.1182/blood-2019-129705

Published: 2019

Journal Articles

Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

Rajni Agarwal, MD, Christopher C. Dvorak, MD, Hye-Sook Kwon, PhD, Janel R Long-Boyle, PharmD, PhD, Susan S Prohaska, PhD MS, Janice W Brown, MD, Anne Le, Alyssa Guttman-Klein, Irving L Weissman, MD, Morton J Cowan, MD, Aaron C. Logan, MD PhD, Kenneth I. Weinberg, MD, Robertson Parkman, MD, Maria-Grazia Roncarolo, MD, Judith A Shizuru, MD PhD

Blood (2019) 134 (Supplement_1): 800.

https://doi.org/10.1182/blood-2019-126239

Published: 2019

Journal Articles

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A. Jonas, MD PhD, Peter T. Curtin, MD, Gary J. Schiller, MD, Deepa Jeyakumar, MD, Matthew J. Wieduwilt, MD PhD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Helen Chow, MD, Leslie G. Oesterich, MD, Aaron C. Logan, MD PhD

Blood (2018) 132 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2018-99-119237

Published: 2018

Journal Articles

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD

Blood (2018) 132 (Supplement 1): 4018.

https://doi.org/10.1182/blood-2018-99-117469

Published: 2018

Journal Articles

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Li-Wen Huang, MD, Chiung-Yu Huang, PhD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Catherine C. Smith, MD, Karin M. Gaensler, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Michael A. Steinman, MD, Rebecca L. Olin, MD

Blood (2018) 132 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2018-99-112025

Published: 2018

Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 897.

https://doi.org/10.1182/blood-2018-99-111531

Published: 2018

Journal Articles

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

David Miklos, MD, Corey S. Cutler, MD MPH, Mukta Arora, MD, Edmund K. Waller, MD PhD FACP, Madan Jagasia, MD MBBS, MS, Iskra Pusic, MD, Mary E. Flowers, MD, Aaron C. Logan, MD PhD, Ryotaro Nakamura, MD, Bruce R. Blazar, MD, Yunfeng Li, PhD, Indu Lal, MD, Jason Dubovsky, PhD, Danelle F. James, MD, Lori Styles, MD, Samantha Jaglowski, MD PhD

Blood (2016) 128 (22): LBA-3.

https://doi.org/10.1182/blood.V128.22.LBA-3.LBA-3

Published: 2016

Journal Articles

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Daniel W. Sherbenou, MD PhD, Blake T. Aftab, PhD, Yang Su, PhD, Christopher R. Behrens, PhD, Arun P. Wiita, MD PhD, Aaron C. Logan, MD PhD, Diego Acosta-Alvear, PhD, Byron C. Hann, MD PhD, Peter Walter, PhD, Xiaobo Wu, MD, John P. Atkinson, MD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Bin Liu, PhD

Blood (2016) 128 (22): 384.

https://doi.org/10.1182/blood.V128.22.384.384

Published: 2016

Journal Articles

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Megan Murnane, M.Sc., Eugen Dhimolea, PhD, Ruojing Li, BS, Megan A. Bariteau, BSc, Diamond D. Wheeler, BS, Rosemary J. Akhurst, PhD, Aaron C. Logan, MD PhD, Pamela Munster, MD, Arun Wiita, MD PhD, Thomas G. Martin, III, MD, Jeffrey L. Wolf, MD PhD, Jun O. Liu, PhD, Constantine S. Mitsiades, MD PhD, Blake T. Aftab, PhD

Blood (2015) 126 (23): 503.

https://doi.org/10.1182/blood.V126.23.503.503

Published: 2015

Journal Articles

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation

Gabriel N. Mannis, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Charalambos Andreadis, MD MSCE, Rebecca L. Olin, MD MSCE, Katie Kong, Malek Faham, MD PhD, Weiyun Z. Ai, MD PhD, Karin ML Gaensler, MD, Peter H. Sayre, MD PhD, Jeffrey L. Wolf, MD PhD, Aaron C. Logan, MD PhD

Blood (2015) 126 (23): 1420.

https://doi.org/10.1182/blood.V126.23.1420.1420

Published: 2015

Journal Articles

Management Strategies for Posterior Reversible Encephalopathy Syndrome (PRES) in Patients Receiving Calcineurin-Inhibitor or Sirolimus Therapy for Hematologic Disorders and Allogeneic Transplantation

Miguel C. Cerejo, DO, Ramon F. Barajas, MD, Soonmee Cha, MD, Aaron C. Logan, MD PhD

Blood (2014) 124 (21): 1144.

https://doi.org/10.1182/blood.V124.21.1144.1144

Published: 2014

Journal Articles

Sequencing-Based Minimal Residual Disease Assessment In T-Cell Malignancies: T-Cell Prolymphocytic Leukemia Case Study

Katherine Sutherland, Katherine Kong, Aaron C. Logan, MD, PhD, Malek Faham, MD, PhD, David B. Miklos, MD, PhD

Blood (2013) 122 (21): 1392.

https://doi.org/10.1182/blood.V122.21.1392.1392

Published: 2013

Journal Articles

Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia

Gabriel N. Mannis, MD, Lloyd E Damon, MD, Weiyun Z. Ai, MD, PhD, Charalambos Andreadis, MD, MS, Karin ML Gaensler, MD, Neel K. Gupta, M.D., Lawrence D. Kaplan, M.D., Andrew D. Leavitt, MD, Aaron C. Logan, MD, PhD, Rebecca L. Olin, MD, MS, Peter H. Sayre, MD, PhD, Catherine C Smith, MD, Jeffrey M Venstrom, MD, Thomas G Martin, III, MD

Blood (2013) 122 (21): 2172.

https://doi.org/10.1182/blood.V122.21.2172.2172

Published: 2013

Journal Articles

Alloreactive T Cell Clonotypes Identified By In Vitro Mixed Lymphoid Reaction and High-Throughput Sequencing Exhibit Increased Frequency In Peripheral Blood Samples From Patients Following Allogeneic Hematopoietic Cell Transplantation For Chronic Lymphocytic Leukemia

Aaron C. Logan, MD, PhD, Mark R. Krampf, MS, Mark Klinger, PhD, Martin Moorhead, PhD, Jianbiao Zheng, PhD, Randall Armstrong, Malek Faham, MD, PhD, Kenneth I Weinberg, MD, David B. Miklos, MD, PhD

Blood (2013) 122 (21): 149.

https://doi.org/10.1182/blood.V122.21.149.149

Published: 2013

Journal Articles

Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia Using High-Throughput Sequencing of Multiple Immunoreceptor Genes Predicts Relapse and Survival After Allogeneic Hematopoietic Cell Transplantation.

Aaron C. Logan, MD, PhD, Nikita Vashi, BS, Malek Faham, MD, PhD, Victoria Carlton, PhD, Ismael Buno, PhD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Mark Klinger, PhD, Tom Willis, PhD, Bing Zhang, MD, Amna Waqar, BS, James L. Zehnder, David B Miklos, MD, PhD

Blood (2012) 120 (21): 2512.

https://doi.org/10.1182/blood.V120.21.2512.2512

Published: 2012

Journal Articles

Anti-CD117 (c-Kit) Monoclonal Antibodies Deplete Human Hematopoietic Stem Cells and Facilitate Their Replacement in Humanized NOD/SCID/IL2Rγ −/− Mice: A Non-Toxic Conditioning Regimen for Allotransplantation

Aaron C. Logan, MD, PhD, Agnieszka Czechowicz, MD, PhD, Benjamin V. Kelley, BS, Theingi M. Thway, PhD, Ivan Magana, Mark R. Krampf, MS, Jessica Poyser, Roger P. Hollis, PhD, Donald B. Kohn, MD, Irving L. Weissman, MD, Judith A. Shizuru, MD, PhD

Blood (2012) 120 (21): 4099.

https://doi.org/10.1182/blood.V120.21.4099.4099

Published: 2012

Journal Articles

Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma

Malek Faham, MD, PhD, Joshua Brody, Holbrook E Kohrt, MD, Ph.D., Aaron C. Logan, MD, PhD, Ranjana H. Advani, MD, Debra K Czerwinski, Wen-Kai Weng, MD, PhD, Robert Negrin, MD, Victoria Carlton, PhD, Ronald Levy, MD

Blood (2012) 120 (21): 582.

https://doi.org/10.1182/blood.V120.21.582.582

Published: 2012

Journal Articles

High-Throughput Immunoglobulin Gene Sequencing Quantifies Minimal Residual Disease in CLL with 10e-6 Sensitivity and Strongly Predicts Relapse After Allogeneic Hematopoietic Cell Transplantation

Aaron C. Logan, MD, PhD, Malek Faham, MD, PhD, Victoria Carlton, PhD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Tom Willis, PhD, Carol D. Jones, Melody B. Zhang, PhD, Amna N. Waqar, James L. Zehnder, MD, David B. Miklos, MD, PhD

Blood (2011) 118 (21): 2542.

https://doi.org/10.1182/blood.V118.21.2542.2542

Published: 2011

NARROW

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation

Management Strategies for Posterior Reversible Encephalopathy Syndrome (PRES) in Patients Receiving Calcineurin-Inhibitor or Sirolimus Therapy for Hematologic Disorders and Allogeneic Transplantation

Sequencing-Based Minimal Residual Disease Assessment In T-Cell Malignancies: T-Cell Prolymphocytic Leukemia Case Study

Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia

Alloreactive T Cell Clonotypes Identified By In Vitro Mixed Lymphoid Reaction and High-Throughput Sequencing Exhibit Increased Frequency In Peripheral Blood Samples From Patients Following Allogeneic Hematopoietic Cell Transplantation For Chronic Lymphocytic Leukemia

Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia Using High-Throughput Sequencing of Multiple Immunoreceptor Genes Predicts Relapse and Survival After Allogeneic Hematopoietic Cell Transplantation.

Anti-CD117 (c-Kit) Monoclonal Antibodies Deplete Human Hematopoietic Stem Cells and Facilitate Their Replacement in Humanized NOD/SCID/IL2Rγ −/− Mice: A Non-Toxic Conditioning Regimen for Allotransplantation

Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma

High-Throughput Immunoglobulin Gene Sequencing Quantifies Minimal Residual Disease in CLL with 10e-6 Sensitivity and Strongly Predicts Relapse After Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only